Clinical Oncology Next Generation Sequencing (NGS) Market Size, Share & Trends Analysis Report By Technology, By Workflow, By Application, By End Use, By Region, And Segment Forecasts, 2019 - 2025

Published: Oct, 2019 | Pages: 155 | Publisher: Grand View Research
Industry: Biotechnology | Report Format: Electronic (PDF)

The global clinical oncology next generation sequencing (NGS) market size is expected to reach USD 1.5 billion by 2025, according to a new report by Grand View Research, Inc., registering a CAGR of 13.2% over the forecast period. Rise in demand for personalized medicine, coupled with growth in next generation sequencing technology, is anticipated to accelerate the growth of NGS technology in clinical diagnostics.

Owing to the fact that next generation sequencing offers several advantages such as sensitivity, accuracy, and speed, this technology is anticipated to drive the oncology clinical diagnostics market. Furthermore, next generation sequencing aids in the assessment of multiple genes in a single assay, thereby eliminating the need to order several tests for determination of underlying mutation.

North America held the dominant share in the global the market for clinical oncology NGS in 2018 owing to increased focus of government bodies on cancer treatment, rise in healthcare expenditure, and presence of adequate infrastructure in the healthcare industry. Asia Pacific is expected to be the fastest-growing regional market throughout the forecast period majorly due to continuous reforms in the healthcare and pharmaceutical industries in the region. Presence of untapped markets in emerging economies in the region will also benefit regional growth. 

Further key findings from the report suggest:

• By technology, targeted sequencing and resequencing held the largest share in 2018 owing to frequent usage in cancer diagnostics. On the other hand, whole-genome sequencing (WGS) is expected to grow at a lucrative rate owing to wide-scale applications and rising demand for the technique

• Based on application, companion diagnostics is anticipated to witness the fastest growth as a consequence of presence of a substantial number of pharmaceutical and diagnostic developers collaborating to commercialize the products. These participants are focused on extensive R&D in companion diagnostics to obtaining regulatory approval for novel assays combined with pharmaceuticals

• On the basis of end use, the clinics segment will expand at a significant growth rate thanks to increase in feasibility for the use of next generation sequencing technology

• North America occupied the largest share owing to increased focus of government bodies on cancer treatment, rise in healthcare expenditure, and presence of adequate healthcare infrastructure

• Asia Pacific is expected to grow at the fastest rate due to continuous reforms in the healthcare and pharmaceutical sectors, accompanied by improvement in reimbursement policies

• Illumina, Inc.; Thermo Fisher Scientific; F. Hoffmann-La Roche Ltd; Agilent Technologies; Myriad Genetics; Beijing Genomics Institute (BGI); Perkin Elmer; Foundation Medicine; Pacific Bioscience; Oxford Nanopore Technologies Ltd; Paradigm Diagnostics; Caris Life Sciences; Partek, Inc.; Eurofins Scientific S.E; and Qiagen N.V. are some of the key participants operating in this market. These participants are engaged in new product development and strategic alliances for enhancing their competitive footprint in the market.

 Table of Contents

Chapter 1 Executive Summary
                 1.1 Market Snapshot
Chapter 2 Research Methodology
                 2.1 Information Procurement
                 2.2 Information or Data Analysis
                 2.3 Market Formulation & Validation
Chapter 3 Market Variables, Trends & Scope
                 3.1 Market Segmentation & Scope
                 3.2 Business Segment Trends
                     3.2.1 Penetration & Growth Prospect Mapping For Application, 2018
                     3.2.2 Penetration & Growth Prospect Mapping For Prominent Industry Players, 2018
                 3.3 Market Variables Analysis
                     3.3.1 Market driver analysis
                         3.3.1.1 Decrease in costs for genetic sequencing
                         3.3.1.2 Advancements in the field of personalized medicine
                         3.3.1.3 Rise in competition amongst prominent market entities
                         3.3.1.4 Growing healthcare expenditure triggering development of effective PM diagnostic & therapeutic procedure for cancer
                         3.3.1.5 Rise in prevalence of cancer
                         3.3.1.6 Growing adoption of NGS over single gene testing
                     3.3.2 Market restraint analysis
                         3.3.2.1 Lack of computational efficiency for data management
                         3.3.2.2 Non-value based NGS reimbursement policy
                 3.4 Business Environment Analysis Tools
                     3.4.1 Swot Analysis, By Factor (Political & Legal, Economic And Technological)
                     3.4.2 Porter's five forces analysis
Chapter 4 Competitive & Vendor Landscape
                 4.1 Strategy Framework
                 4.2 Market Participation Categorization
Chapter 5 Clinical Oncology Next Generation Sequencing Market Categorization: Technology Estimates & Trend Analysis
                 5.1 Clinical Oncology NGS Market: Technology Movement Analysis
                 5.2 Whole Genome Sequencing
                     5.2.1 Whole genome sequencing for clinical oncology market, 2014 - 2025 (USD Million)
                 5.3 Whole Exome Sequencing
                     5.3.1 Whole exome sequencing for clinical oncology market, 2014 - 2025 (USD Million)
                 5.4 Targeted Sequencing & Resequencing
                     5.4.1 Targeted sequencing and resequencing for clinical oncology market, 2014 - 2025 (USD Million)
Chapter 6 Clinical Oncology Next Generation Sequencing Market Categorization: Workflow Estimates & Trend Analysis
                 6.1 Clinical Oncology NGS Market: Workflow Movement Analysis
                 6.2 NGS Pre-Sequencing
                     6.2.1 NGS pre-sequencing for clinical oncology market, 2014 - 2025 (USD Million)
                 6.3 NGS Sequencing
                     6.3.1 NGS sequencing for clinical oncology market, 2014 - 2025 (USD Million)
                 6.4 NGS Data Analysis
                     6.4.1 NGS data analysis for clinical oncology market, 2014 - 2025 (USD Million)
Chapter 7 Clinical Oncology Next Generation Sequencing Market Categorization: Application Estimates & Trend Analysis
                 7.1 Clinical Oncology NGS Market: Application Movement Analysis
                 7.2 Screening
                     7.2.1 Screening clinical oncology NGS market, 2014 - 2025 (USD Million)
                     7.2.2 Sporadic Cancer
                         7.2.2.1 Sporadic cancer screening clinical oncology NGS market, 2014 - 2025 (USD Million)
                     7.2.3 Inherited cancer
                         7.2.3.1 Inherited cancer screening clinical oncology NGS market, 2014 - 2025 (USD Million)
                 7.3 Companion Diagnostics
                     7.3.1 Companion diagnostics clinical oncology NGS market, 2014 - 2025 (USD Million)
                 7.4 Other Diagnostics
                     7.4.1 Other diagnostics clinical oncology NGS market, 2014 - 2025 (USD Million)
Chapter 8 Clinical Oncology Next Generation Sequencing Market Categorization: End Use Estimates & Trend Analysis
                 8.1 Clinical Oncology NGS Market: End Use Movement Analysis
                 8.2 Hospitals
                     8.2.1 Hospitals clinical oncology NGS market, 2014 - 2025 (USD Million)
                 8.3 Clinics
                     8.3.1 Clinics clinical oncology NGS market, 2014 - 2025 (USD Million)
                 8.4 Laboratories
                     8.4.1 Laboratories clinical oncology NGS market, 2014 - 2025 (USD Million)
Chapter 9 Clinical Oncology Next Generation Sequencing Market Categorization: Regional Estimates & Trend Analysis, by Technology, Workflow, Application, & End Use
                 9.1 Clinical Oncology NGS Market Share By Region, 2018 & 2025
                 9.2 North America
                     9.2.1 North America clinical oncology NGS market, 2014 - 2025 (USD Million)
                     9.2.2 U.S.
                         9.2.2.1 U.S. clinical oncology NGS market, by technology, 2014 - 2025 (USD Million)
                         9.2.2.2 U.S. clinical oncology NGS market, by workflow, 2014 - 2025 (USD Million)
                         9.2.2.3 U.S. clinical oncology NGS market, by application, 2014 - 2025 (USD Million)
                         9.2.2.4 U.S. clinical oncology NGS market, by end use, 2014 - 2025 (USD Million)
                     9.2.3 Canada
                         9.2.3.1 Canada clinical oncology NGS market, by technology, 2014 - 2025 (USD Million)
                         9.2.3.2 Canada clinical oncology NGS market, by workflow, 2014 - 2025 (USD Million)
                         9.2.3.3 Canada clinical oncology NGS market, by application, 2014 - 2025 (USD Million)
                         9.2.3.4 Canada clinical oncology NGS market, by end use, 2014 - 2025 (USD Million)
                 9.3 Europe
                     9.3.1 Europe clinical oncology NGS market, 2014 - 2025 (USD Million)
                     9.3.2 Germany
                         9.3.2.1 Germany clinical oncology NGS market, by technology, 2014 - 2025 (USD Million)
                         9.3.2.2 Germany clinical oncology NGS market, by workflow, 2014 - 2025 (USD Million)
                         9.3.2.3 Germany clinical oncology NGS market, by application, 2014 - 2025 (USD Million)
                         9.3.2.4 Germany clinical oncology NGS market, by end use, 2014 - 2025 (USD Million)
                     9.3.3 U.K.
                         9.3.3.1 U.K. clinical oncology NGS market, by technology, 2014 - 2025 (USD Million)
                         9.3.3.2 U.K. clinical oncology NGS market, by workflow, 2014 - 2025 (USD Million)
                         9.3.3.3 U.K. clinical oncology NGS market, by application, 2014 - 2025 (USD Million)
                         9.3.3.4 U.K. clinical oncology NGS market, by end use, 2014 - 2025 (USD Million)
                 9.4 Asia Pacific
                     9.4.1 Asia Pacific clinical oncology NGS market, 2014 - 2025 (USD Million)
                     9.4.2 Japan
                         9.4.2.1 Japan clinical oncology NGS market, by technology, 2014 - 2025 (USD Million)
                         9.4.2.2 Japan clinical oncology NGS market, by workflow, 2014 - 2025 (USD Million)
                         9.4.2.3 Japan clinical oncology NGS market, by application, 2014 - 2025 (USD Million)
                         9.4.2.4 Japan clinical oncology NGS market, by end use, 2014 - 2025 (USD Million)
                     9.4.3 China
                         9.4.3.1 China clinical oncology NGS market, by technology, 2014 - 2025 (USD Million)
                         9.4.3.2 China clinical oncology NGS market, by workflow, 2014 - 2025 (USD Million)
                         9.4.3.3 China clinical oncology NGS market, by application, 2014 - 2025 (USD Million)
                         9.4.3.4 China clinical oncology NGS market, by end use, 2014 - 2025 (USD Million)
                 9.5 Latin America
                     9.5.1 Latin America clinical oncology NGS market, 2014 - 2025 (USD Million)
                     9.5.2 Brazil
                         9.5.2.1 Brazil clinical oncology NGS market, by technology, 2014 - 2025 (USD Million)
                         9.5.2.2 Brazil clinical oncology NGS market, by workflow, 2014 - 2025 (USD Million)
                         9.5.2.3 Brazil clinical oncology NGS market, by application, 2014 - 2025 (USD Million)
                         9.5.2.4 Brazil clinical oncology NGS market, by end use, 2014 - 2025 (USD Million)
                 9.6 Middle East & Africa (MEA)
                     9.6.1 Middle East & Africa clinical oncology NGS market, 2014 - 2025 (USD Million)
                     9.6.2 South Africa
                         9.6.2.1 South Africa clinical oncology NGS market, by technology, 2014 - 2025 (USD Million)
                         9.6.2.2 South Africa clinical oncology NGS market, by workflow, 2014 - 2025 (USD Million)
                         9.6.2.3 South Africa clinical oncology NGS market, by application, 2014 - 2025 (USD Million)
                         9.6.2.4 South Africa clinical oncology NGS market, by end use, 2014 - 2025 (USD Million)
Chapter 10 Clinical Oncology NGS Market: Company Profiles
                 10.1 Key Companies Profiled
                 10.2 Illumina, Inc.
                     10.2.1 Company overview
                         10.2.1.1 Financial performance
                     10.2.2 Product benchmarking
                     10.2.3 Strategic initiatives
                 10.3 F. Hoffmann-La Roche Ltd
                     10.3.1 Company overview
                         10.3.1.1 Financial performance
                     10.3.2 Product benchmarking
                     10.3.3 Strategic initiatives
                 10.4 Agilent Technologies
                     10.4.1 Company overview
                     10.4.2 Financial performance
                     10.4.3 Product benchmarking
                     10.4.4 Strategic initiatives
                 10.5 Thermo Fisher Scientific Inc.
                     10.5.1 Company overview
                     10.5.2 Financial performance
                     10.5.3 Product benchmarking
                     10.5.4 Strategic initiatives
                 10.6 Myriad Genetics, Inc.
                     10.6.1 Company overview
                     10.6.2 Financial performance
                     10.6.3 Product benchmarking
                     10.6.4 Strategic initiatives
                 10.7 Beijing Genomics Institute (BGI)
                     10.7.1 Company overview
                     10.7.2 Financial performance
                     10.7.3 Product benchmarking
                     10.7.4 Strategic initiatives
                 10.8 Qiagen NV
                     10.8.1 Company overview
                     10.8.2 Financial performance
                     10.8.3 Product benchmarking
                     10.8.4 Strategic initiatives
                 10.9 Perkin Elmer, Inc.
                     10.9.1 Company overview
                     10.9.2 Financial performance
                     10.9.3 Product benchmarking
                     10.9.4 Strategic initiatives
                 10.10 Pacific Bioscience, Inc.
                     10.10.1 Company overview
                     10.10.2 Financial performance
                     10.10.3 Product benchmarking
                     10.10.4 Strategic initiatives
                 10.11 Partek, Inc.
                     10.11.1 Company overview
                     10.11.2 Financial performance
                     10.11.3 Product benchmarking
                     10.11.4 Strategic initiatives
                 10.12 Foundation Medicine Inc.
                     10.12.1 Company overview
                     10.12.2 Financial performance
                     10.12.3 Product benchmarking
                     10.12.4 Strategic Initiatives
                 10.13 Oxford Nanopore Technologies Ltd.
                     10.13.1 Company overview
                     10.13.2 Financial performance
                     10.13.3 Product benchmarking
                     10.13.4 Strategic Initiatives
                 10.14 Paradigm Diagnostics, Inc
                     10.14.1 Company overview
                     10.14.2 Financial performance
                     10.14.3 Product benchmarking
                     10.14.4 Strategic initiatives
                 10.15 Caris Life Sciences
                     10.15.1 Company overview
                     10.15.2 Financial performance
                     10.15.3 Product benchmarking
                     10.15.4 Strategic Initiatives
                 10.16 Eurofins Scientific S.E.
                     10.16.1 Company overview
                     10.16.2 Financial performance
                     10.16.3 Product benchmarking
                     10.16.4 Strategic initiatives

List of Tables

TABLE 1 Healthcare expenditure levels, 2012
TABLE 2 Cancer incidence and mortality, by region, 2018
TABLE 3 Genes associated with breast and ovarian cancer that can be sequenced by NGS panel
TABLE 4 FDA-Approved NGS Tumour-Profiling Tests for Companion Diagnostics
TABLE 5 Gene-panels used in clinics for Hereditary Breast/Ovarian Cancer (HBOC)
TABLE 6 North America clinical oncology NGS market estimates & forecasts, by technology, 2014 - 2025 (USD Million)
TABLE 7 North America clinical oncology NGS market estimates & forecasts, by workflow, 2014 - 2025 (USD Million)
TABLE 8 North America clinical oncology NGS market estimates & forecasts, by application, 2014 - 2025 (USD Million)
TABLE 9 North America clinical oncology NGS screening market estimates & forecasts, by application, 2014 - 2025 (USD Million)
TABLE 10 North America clinical oncology NGS market estimates & forecasts, by end use, 2014 - 2025 (USD Million)
TABLE 11 U.S. clinical oncology NGS market estimates & forecasts, by technology, 2014 - 2025 (USD Million)
TABLE 12 U.S. clinical oncology NGS market estimates & forecasts, by workflow, 2014 - 2025 (USD Million)
TABLE 13 U.S. clinical oncology NGS market estimates & forecasts, by application, 2014 - 2025 (USD Million)
TABLE 14 U.S. clinical oncology NGS screening market estimates & forecasts, by application, 2014 - 2025 (USD Million)
TABLE 15 U.S. clinical oncology NGS market estimates & forecasts, by end use, 2014 - 2025 (USD Million)
TABLE 16 Canada clinical oncology NGS market estimates & forecasts, by technology, 2014 - 2025 (USD Million)
TABLE 17 Canada clinical oncology NGS market estimates & forecasts, by workflow, 2014 - 2025 (USD Million)
TABLE 18 Canada clinical oncology NGS market estimates & forecasts, by application, 2014 - 2025 (USD Million)
TABLE 19 Canada clinical oncology NGS screening market estimates & forecasts, by application, 2014 - 2025 (USD Million)
TABLE 20 Canada clinical oncology NGS market estimates & forecasts, by end use, 2014 - 2025 (USD Million)
TABLE 21 Europe clinical oncology NGS market estimates & forecasts, by technology, 2014 - 2025 (USD Million)
TABLE 22 Europe clinical oncology NGS market estimates & forecasts, by workflow, 2014 - 2025 (USD Million)
TABLE 23 Europe clinical oncology NGS market estimates & forecasts, by application, 2014 - 2025 (USD Million)
TABLE 24 Europe clinical oncology NGS screening market estimates & forecasts, by application, 2014 - 2025 (USD Million)
TABLE 25 Europe clinical oncology NGS market estimates & forecasts, by end use, 2014 - 2025 (USD Million)
TABLE 26 Germany clinical oncology NGS market estimates & forecasts, by technology, 2014 - 2025 (USD Million)
TABLE 27 Germany clinical oncology NGS market estimates & forecasts, by workflow, 2014 - 2025 (USD Million)
TABLE 28 Germany clinical oncology NGS market estimates & forecasts, by application, 2014 - 2025 (USD Million)
TABLE 29 Germany clinical oncology NGS screening market estimates & forecasts, by application, 2014 - 2025 (USD Million)
TABLE 30 Germany clinical oncology NGS market estimates & forecasts, by end use, 2014 - 2025 (USD Million)
TABLE 31 U.K. clinical oncology NGS market estimates & forecasts, by technology, 2014 - 2025 (USD Million)
TABLE 32 U.K. clinical oncology NGS market estimates & forecasts, by workflow, 2014 - 2025 (USD Million)
TABLE 33 U.K. clinical oncology NGS market estimates & forecasts, by application, 2014 - 2025 (USD Million)
TABLE 34 U.K. clinical oncology NGS screening market estimates & forecasts, by application, 2014 - 2025 (USD Million)
TABLE 35 U.K. clinical oncology NGS market estimates & forecasts, by end use, 2014 - 2025 (USD Million)
TABLE 36 Asia Pacific clinical oncology NGS market estimates & forecasts, by technology, 2014 - 2025 (USD Million)
TABLE 37 Asia Pacific clinical oncology NGS market estimates & forecasts, by workflow, 2014 - 2025 (USD Million)
TABLE 38 Asia Pacific clinical oncology NGS market estimates & forecasts, by application, 2014 - 2025 (USD Million)
TABLE 39 Asia Pacific clinical oncology NGS screening market estimates & forecasts, by application, 2014 - 2025 (USD Million)
TABLE 40 Asia Pacific clinical oncology NGS market estimates & forecasts, by end use, 2014 - 2025 (USD Million)
TABLE 41 Japan clinical oncology NGS market estimates & forecasts, by technology, 2014 - 2025 (USD Million)
TABLE 42 Japan clinical oncology NGS market estimates & forecasts, by workflow, 2014 - 2025 (USD Million)
TABLE 43 Japan clinical oncology NGS market estimates & forecasts, by application, 2014 - 2025 (USD Million)
TABLE 44 Japan clinical oncology NGS screening market estimates & forecasts, by application, 2014 - 2025 (USD Million)
TABLE 45 Japan clinical oncology NGS market estimates & forecasts, by end use, 2014 - 2025 (USD Million)
TABLE 46 China clinical oncology NGS market estimates & forecasts, by technology, 2014 - 2025 (USD Million)
TABLE 47 China clinical oncology NGS market estimates & forecasts, by workflow, 2014 - 2025 (USD Million)
TABLE 48 China clinical oncology NGS market estimates & forecasts, by application, 2014 - 2025 (USD Million)
TABLE 49 China clinical oncology NGS screening market estimates & forecasts, by application, 2014 - 2025 (USD Million)
TABLE 50 China clinical oncology NGS market estimates & forecasts, by end use, 2014 - 2025 (USD Million)
TABLE 51 Latin America clinical oncology NGS market estimates & forecasts, by technology, 2014 - 2025 (USD Million)
TABLE 52 Latin America clinical oncology NGS market estimates & forecasts, by workflow, 2014 - 2025 (USD Million)
TABLE 53 Latin America clinical oncology NGS market estimates & forecasts, by application, 2014 - 2025 (USD Million)
TABLE 54 Latin America clinical oncology NGS screening market estimates & forecasts, by application, 2014 - 2025 (USD Million)
TABLE 55 Latin America clinical oncology NGS market estimates & forecasts, by end use, 2014 - 2025 (USD Million)
TABLE 56 Brazil clinical oncology NGS market estimates & forecasts, by technology, 2014 - 2025 (USD Million)
TABLE 57 Brazil clinical oncology NGS market estimates & forecasts, by workflow, 2014 - 2025 (USD Million)
TABLE 58 Brazil clinical oncology NGS market estimates & forecasts, by application, 2014 - 2025 (USD Million)
TABLE 59 Brazil clinical oncology NGS screening market estimates & forecasts, by application, 2014 - 2025 (USD Million)
TABLE 60 Brazil clinical oncology NGS market estimates & forecasts, by end use, 2014 - 2025 (USD Million)
TABLE 61 Middle East & Africa clinical oncology NGS market estimates & forecasts, by technology, 2014 - 2025 (USD Million)
TABLE 62 Middle East & Africa clinical oncology NGS market estimates & forecasts, by workflow, 2014 - 2025 (USD Million)
TABLE 63 Middle East & Africa clinical oncology NGS market estimates & forecasts, by application, 2014 - 2025 (USD Million)
TABLE 64 Middle East & Africa clinical oncology NGS screening market estimates & forecasts, by application, 2014 - 2025 (USD Million)
TABLE 65 Middle East & Africa clinical oncology NGS market estimates & forecasts, by end use, 2014 - 2025 (USD Million)
TABLE 66 South Africa clinical oncology NGS market estimates & forecasts, by technology, 2014 - 2025 (USD Million)
TABLE 67 South Africa clinical oncology NGS market estimates & forecasts, by workflow, 2014 - 2025 (USD Million)
TABLE 68 South Africa clinical oncology NGS market estimates & forecasts, by application, 2014 - 2025 (USD Million)
TABLE 69 South Africa clinical oncology NGS screening market estimates & forecasts, by application, 2014 - 2025 (USD Million)
TABLE 70 South Africa clinical oncology NGS market estimates & forecasts, by end use, 2014 - 2025 (USD Million)

List of Figures

FIG. 1 Market snapshot
FIG. 2 Market research process
FIG. 3 Information procurement
FIG. 4 Primary research pattern
FIG. 5 Market research approaches
FIG. 6 Value chain based sizing & forecasting
FIG. 7 QFD modelling for market share assessment
FIG. 8 Market trends & outlook
FIG. 9 Market segmentation & scope
FIG. 10 Penetration & growth prospect mapping for application, 2018
FIG. 11 Penetration & growth prospect mapping for prominent industry players, 2018
FIG. 12 Market driver relevance analysis (Current & future impact)
FIG. 13 Cost per raw mega base (Mb) of DNA sequence (USD)
FIG. 14 Cost per genome
FIG. 15 Expected rise in expenditure for cancer treatment (USD Billion)
FIG. 16 Number of new cancer cases in the World, 2018
FIG. 17 Market restraint relevance analysis (Current & future impact)
FIG. 18 SWOT Analysis, By Factor (political & legal, economic and technological)
FIG. 19 Porter's Five Forces Analysis
FIG. 20 Strategy framework
FIG. 21 Participant categorization
FIG. 22 Clinical oncology NGS market: Technology outlook key takeaways
FIG. 23 Clinical oncology NGS market: Technology movement analysis
FIG. 24 Whole genome sequencing for clinical oncology market, 2014 - 2025 (USD Million)
FIG. 25 Whole exome sequencing for clinical oncology market, 2014 - 2025 (USD Million)
FIG. 26 Targeted sequencing and resequencing for clinical oncology market, 2014 - 2025 (USD Million)
FIG. 27 Clinical oncology NGS market: Workflow outlook key takeaways
FIG. 28 Clinical oncology NGS market: Workflow movement analysis
FIG. 29 NGS pre-sequencing for clinical oncology market, 2014 - 2025 (USD Million)
FIG. 30 NGS sequencing for clinical oncology market, 2014 - 2025 (USD Million)
FIG. 31 NGS data analysis for clinical oncology market, 2014 - 2025 (USD Million)
FIG. 32 Clinical oncology NGS market: Application outlook key takeaways
FIG. 33 Clinical oncology NGS market: Application movement analysis
FIG. 34 Screening clinical oncology NGS market, 2014 - 2025 (USD Million)
FIG. 35 Sporadic cancer screening clinical oncology NGS market, 2014 - 2025 (USD Million)
FIG. 36 Lifetime cancer risks for common cancers
FIG. 37 Inherited cancer screening clinical oncology NGS market, 2014 - 2025 (USD Million)
FIG. 38 Companion diagnostics clinical oncology NGS market, 2014 - 2025 (USD Million)
FIG. 39 Other diagnostics clinical oncology NGS market, 2014 - 2025 (USD Million)
FIG. 40 Clinical oncology NGS market: End use outlook key takeaways
FIG. 41 Clinical oncology NGS market: End use movement analysis
FIG. 42 Hospitals clinical oncology NGS market, 2014 - 2025 (USD Million)
FIG. 43 Clinics clinical oncology NGS market, 2014 - 2025 (USD Million)
FIG. 44 Laboratories clinical oncology NGS market, 2014 - 2025 (USD Million)
FIG. 45 Regional market place: Key takeaway
FIG. 46 Clinical oncology NGS market: Regional outlook, 2018 & 2025
FIG. 47 North America clinical oncology NGS market, 2014 - 2025 (USD Million)
FIG. 48 U.S. clinical oncology NGS market, 2014 - 2025 (USD Million)
FIG. 49 Canada clinical oncology NGS market, 2014 - 2025 (USD Million)
FIG. 50 Europe clinical oncology NGS market, 2014 - 2025 (USD Million)
FIG. 51 Germany clinical oncology NGS market, 2014 - 2025 (USD Million)
FIG. 52 U.K. clinical oncology NGS market, 2014 - 2025 (USD Million)
FIG. 53 Asia Pacific clinical oncology NGS market, 2014 - 2025 (USD Million)
FIG. 54 Japan clinical oncology NGS market, 2014 - 2025 (USD Million)
FIG. 55 China clinical oncology NGS market, 2014 - 2025 (USD Million)
FIG. 56 Latin America clinical oncology NGS market, 2014 - 2025 (USD Million)
FIG. 57 Brazil clinical oncology NGS market, 2014 - 2025 (USD Million)
FIG. 58 Middle East & Africa clinical oncology NGS market, 2014 - 2025 (USD Million)
FIG. 59 South Africa clinical oncology NGS market, 2014 - 2025 (USD Million)
FIG. 60 Key companies profiled